Dissolution

BioFLUX

BioFlux™ system can be combined with the in situ Fiber Optic UV System to study absorption potential of drugs final dosages.

BioFLUX Product ImageBioFLUX Product ImageBioFLUX Product Image
BioFLUX Product ImageBioFLUX Product ImageBioFLUX Product Image
benefits

BioFlux™ system can be combined with the in situ Fiber Optic UV System to study absorption potential of drugs final dosages.

Used for conducting simultaneous dissolution-absorption studies.

Assess the complex of interplay between solubility, permeability and dissolution rate in-vitro.

Evaluate whether certain formulation changes will affect the bio-performance of a certain drug product.

BioFLUX

Configurations

Application

The In-Situ UV Probe-Based Dissolution System

The BioFLUX™ system consists of an absorption (receiver) chamber integrated with a lipophilic membrane, overhead stirrer and fiber optic (FO) UV probe that is inserted in to a modified cover of a miniaturized 500 mL vessel of USP II dissolution apparatus.

The phospholipid-covered artificial permeation membrane separates the dissolution (donor) compartment from the receiver compartment, containing Pion Acceptor Sink Buffer at pH 7.4. The dissolution compartment typically holds 200 – 250 mL of compendial or biorelevant dissolution buffer. The modified vessel cover allows fiber-optic UV probes to be positioned in both the donor and receiver compartments to monitor real-time concentration kinetic in both chambers. Concentration monitoring is enabled by connecting the fiber optic UV probes to the Rainbow Dynamic Dissolution Monitor® instrument.

The In-Situ UV Probe-Based Dissolution System
The In-Situ UV Probe-Based Dissolution System

Improve Process and Decision Making with Better In Vitro Insights
Features

Improve Process and Decision Making with Better In Vitro Insights

The BioFLUX™ in conjunction with Rainbow R6

  • Provided valuable information about permeability-solubility interplay of poorly soluble drugs during formulation development;
  • Allows to perform experiments at biorelevant volumes (200-250mL) for late stage formulation development or bioequivalence studies;
  • Designed to work with USP II apparatuses.